These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11706406)

  • 21. An audience with Tatiana Prowell. Interviewed by Asher Mullard.
    Prowell T
    Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091
    [No Abstract]   [Full Text] [Related]  

  • 22. Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 1. Selective enzyme inhibitors.
    Seiler N
    Curr Drug Targets; 2003 Oct; 4(7):537-64. PubMed ID: 14535654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New trial designs to assess antitumor and antiproliferative agents in prostate cancer.
    Stadler W
    Invest New Drugs; 2002 May; 20(2):201-8. PubMed ID: 12099580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proprotein convertase inhibition: Paralyzing the cell's master switches.
    Klein-Szanto AJ; Bassi DE
    Biochem Pharmacol; 2017 Sep; 140():8-15. PubMed ID: 28456517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib as a paradigm of targeted therapies.
    Druker BJ
    Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basis and importance of Src as a target in cancer.
    Levin VA
    Cancer Treat Res; 2004; 119():89-119. PubMed ID: 15164875
    [No Abstract]   [Full Text] [Related]  

  • 28. New Clinical Trial Designs Hasten Approvals for Targeted Therapies.
    Schmidt C
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26944760
    [No Abstract]   [Full Text] [Related]  

  • 29. Early Phase Clinical Trial Designs - State of Play and Adapting for the Future.
    Harrington JA; Hernandez-Guerrero TC; Basu B
    Clin Oncol (R Coll Radiol); 2017 Dec; 29(12):770-777. PubMed ID: 29108786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.
    Gradishar WJ
    Invest New Drugs; 1997; 15(1):49-59. PubMed ID: 9195289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
    Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Seymour LK; Eisenhauer EA
    Eur J Cancer; 2008 Jan; 44(1):19-24. PubMed ID: 17890079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opportunities and challenges in the development of kinase inhibitor therapy for cancer.
    Sawyers CL
    Genes Dev; 2003 Dec; 17(24):2998-3010. PubMed ID: 14701871
    [No Abstract]   [Full Text] [Related]  

  • 33. Development of target-based antineoplastic agents.
    Stadler WM; Ratain MJ
    Invest New Drugs; 2000 Feb; 18(1):7-16. PubMed ID: 10830137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trial design for cancer (cell)-specific anticancer therapies.
    van Alphen RJ; Verweij J; Eskens FA
    Expert Opin Ther Targets; 2007 Sep; 11(9):1137-41. PubMed ID: 17845141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic targeting of the receptor tyrosine kinase Met.
    Sattler M; Ma PC; Salgia R
    Cancer Treat Res; 2004; 119():121-38. PubMed ID: 15164876
    [No Abstract]   [Full Text] [Related]  

  • 36. Experimental chemotherapeutic agents for the treatment of colorectal carcinoma.
    O'Reilly S; Rowinsky EK
    Hematol Oncol Clin North Am; 1997 Aug; 11(4):721-58. PubMed ID: 9257153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Designing transformative clinical trials in the cancer genome era.
    Sleijfer S; Bogaerts J; Siu LL
    J Clin Oncol; 2013 May; 31(15):1834-41. PubMed ID: 23589555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I clinical trials: adapting methodology to face new challenges.
    Kerr DJ
    Ann Oncol; 1994; 5 Suppl 4():67-70. PubMed ID: 8060900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.